FrancophonIA/DGT-Translation_Memory huggingface dataset:
English: Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H. and Marcos, R. (1995), Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures, Mutation Res., 341, 169-184.
French: Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H. et Marcos, R. (1995), Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures, Mutation Res., 341, 169-184.
Portuguese: Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H., Marcos, R. (1995). Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures. Mutation Res., 341, 169-184.
Swedish: Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H. och Marcos, R. (1995), Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures, Mutation Res., 341, 169–184.
Finnish: Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H. ja Marcos, R. (1995). Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures. Mutation Res. 341, s. 169–184.
Czech: Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H. and Marcos, R. (1995), Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures, Mutation Res., 341, 169–184.
Slovak: Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H. and Marcos, R. (1995), Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures, Mutation Res., 341, 169 – 184.
Polish: Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H. and Marcos, R. (1995), Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures, Mutation Res., 341, 169–184.
Slovenian: Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H. and Marcos, R. (1995), Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures, Mutation Res., 341, 169–184.
Estonian: Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H. and Marcos, R. (1995), Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures, Mutation Res., 341, 169–184.
Latvian: Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H. and Marcos, R. (1995), Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures, Mutation Res., 341, 169-184.
Lithuanian: Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H. and Marcos, R. (1995), Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures, Mutation Res., 341, 169–184.
Maltese: Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H. u Marcos, R. (1995), Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures, Mutation Res., 341, 169–184.
English: Mutagenesis 35, 191-201.
Portuguese: Mutagenesis, 35, 191-201.
Swedish: Mutagenesis 35, 191–201.
Finnish: Mutagenesis 35, s. 191–201.
Czech: Mutagenesis 35, 191–201.
Slovak: Mutagenesis 35, 191 – 201.
Polish: Mutagenesis 35, 191–201.
Slovenian: Mutagenesis 35, 191–201.
Estonian: Mutagenesis 35, 191–201.
Lithuanian: Mutagenesis 35, 191–201.
Maltese: Mutagenesis 35, 191–201.
English: , An Application of Acridine Orange Fluorescent Staining to the Micronucleus Test, Mutation Res., 120, 241-247.
Portuguese: An Application of Acridine Orange Fluorescent Staining to the Micronucleus Test. Mutation Res., 120, 241-247.
Swedish: , An Application of Acridine Orange Fluorescent Staining to the Micronucleus Test, Mutation Res., 120, 241–247.
Finnish: An Application of Acridine Orange Fluorescent Staining to the Micronucleus Test. Mutation Res. 120, s. 241–247.
Czech: , An Application of Acridine Orange Fluorescent Staining to the Micronucleus Test, Mutation Res., 120, 241–247.
Slovak: , An Application of Acridine Orange Fluorescent Staining to the Micronucleus Test, Mutation Res., 120, 241 – 247.
Polish: , An Application of Acridine Orange Fluorescent Staining to the Micronucleus Test, Mutation Res., 120, 241–247.
Slovenian: , An Application of Acridine Orange Fluorescent Staining to the Micronucleus Test, Mutation Res., 120, 241–247.
Estonian: , An Application of Acridine Orange Fluorescent Staining to the Micronucleus Test, Mutation Res., 120, 241–247.
Lithuanian: , An Application of Acridine Orange Fluorescent Staining to the Micronucleus Test, Mutation Res., 120, 241–247.
Maltese: , An Application of Acridine Orange Fluorescent Staining to the Micronucleus Test, Mutation Res., 120, 241–247.
English: MacGregor, J. T., Wehr, C. M., and Langlois, R. G. (1983), A Simple Fluorescent Staining Procedure for Micronuclei and RNA in Erythrocytes Using Hoechst 33258 and Pyronin Y, Mutation Res., 120, 269-275.
French: MacGregor, J. T., Wehr, C. M., et Langlois, R. G. (1983), A Simple Fluorescent Staining Procedure for Micronuclei and RNA in Erythrocytes Using Hoechst 33258 and Pyronin Y, Mutation Res., 120, 269-275.
Portuguese: MacGregor, J. T., Wehr, C. M., Langlois, R. G. (1983). A Simple Fluorescent Staining Procedure for Micronuclei and RNA in Erythrocytes Using Hoechst 33258 and Pyronin Y. Mutation Res., 120, 269-275.
Swedish: MacGregor, J. T., Wehr, C. M. och Langlois, R. G. (1983), A Simple Fluorescent Staining Procedure for Micronuclei and RNA in Erythrocytes Using Hoechst 33258 and Pyronin Y, Mutation Res., 120, 269–275.
Finnish: MacGregor, J. T., Wehr, C. M. ja Langlois, R. G. (1983). A Simple Fluorescent Staining Procedure for Micronuclei and RNA in Erythrocytes Using Hoechst 33258 and Pyronin Y. Mutation Res. 120, s. 269–275.
Czech: MacGregor, J. T., Wehr, C. M., and Langlois, R. G. (1983), A Simple Fluorescent Staining Procedure for Micronuclei and RNA in Erythrocytes Using Hoechst 33258 and Pyronin Y, Mutation Res., 120, 269–275.
Slovak: MacGregor, J. T., Wehr, C. M., and Langlois, R. G. (1983), A Simple Fluorescent Staining Procedure for Micronuclei and RNA in Erythrocytes Using Hoechst 33258 and Pyronin Y, Mutation Res., 120, 269 – 275.
Polish: MacGregor, J. T., Wehr, C. M., and Langlois, R. G. (1983), A Simple Fluorescent Staining Procedure for Micronuclei and RNA in Erythrocytes Using Hoechst 33258 and Pyronin Y, Mutation Res., 120, 269–275.
Slovenian: MacGregor, J. T., Wehr, C. M., and Langlois, R. G. (1983), A Simple Fluorescent Staining Procedure for Micronuclei and RNA in Erythrocytes Using Hoechst 33258 and Pyronin Y, Mutation Res., 120, 269–275.
Estonian: MacGregor, J. T., Wehr, C. M., and Langlois, R. G. (1983), A Simple Fluorescent Staining Procedure for Micronuclei and RNA in Erythrocytes Using Hoechst 33258 and Pyronin Y, Mutation Res., 120, 269–275.
Latvian: MacGregor, J. T., Wehr, C. M., and Langlois, R. G. (1983), A Simple Fluorescent Staining Procedure for Micronuclei and RNA in Erythrocytes Using Hoechst 33258 and Pyronin Y, Mutation Res., 120, 269-275.
Lithuanian: MacGregor, J. T., Wehr, C. M., and Langlois, R. G. (1983), A Simple Fluorescent Staining Procedure for Micronuclei and RNA in Erythrocytes Using Hoechst 33258 and Pyronin Y, Mutation Res., 120, 269–275.
Maltese: MacGregor, J. T., Wehr, C. M., u Langlois, R. G. (1983), A Simple Fluorescent Staining Procedure for Micronuclei and RNA in Erythrocytes Using Hoechst 33258 u Pyronin Y, Mutation Res., 120, 269–275.
English: , An application of acridine orange fluorescent staining to the micronucleus test, Mutation Res., 120, 241-247.
Portuguese: An application of acridine orange fluorescent staining to the micronucleus test. Mutation Res., 120, 241-247.
Swedish: , An application of acridine orange fluorescent staining to the micronucleus test, Mutation Res., 120, 241–247.
Finnish: An application of acridine orange fluorescent staining to the micronucleus test. Mutation Res. 120, s. 241–247.
Czech: , An application of acridine orange fluorescent staining to the micronucleus test, Mutation Res., 120, 241–247.
Slovak: , An application of acridine orange fluorescent staining to the micronucleus test, Mutation Res., 120, 241 – 247.
Polish: , An application of acridine orange fluorescent staining to the micronucleus test, Mutation Res., 120, 241–247.
Slovenian: , An application of acridine orange fluorescent staining to the micronucleus test, Mutation Res., 120, 241–247.
Estonian: , An application of acridine orange fluorescent staining to the micronucleus test, Mutation Res., 120, 241–247.
Lithuanian: , An application of acridine orange fluorescent staining to the micronucleus test, Mutation Res., 120, 241–247.
Maltese: , An application of acridine orange fluorescent staining to the micronucleus test, Mutation Res., 120, 241–247.
English: This does not necessarily imply that in all instances the LLNA: DA should be used in place of the LLNA or guinea pig tests (i.e. B.6; OECD Test Guideline 406) (14), but rather that the assay is of equal merit and may be employed as an alternative in which positive and negative results generally no longer require further confirmation (10) (11). The testing laboratory should consider all available information on the test substance prior to conducting the study. Such information will include the identity and chemical structure of the test substance; its physicochemical properties; the results of any other in vitro or in vivo toxicity tests on the test substance; and toxicological data on structurally related chemicals. This information should be considered in order to determine whether the LLNA: DA is appropriate for the test substance (given the incompatibility of limited types of chemicals with the LLNA: DA (see paragraph 5) and to aid in dose selection.
Czech: To však nutně neznamená, že by se metoda LLNA: DA měla používat ve všech případech namísto metody LLNA nebo namísto zkoušek na morčatech (tzn. podle kapitoly B.6 této přílohy a zkušební metodiky OECD č. 406 (14); znamená to spíše, že tato metoda má stejnou hodnotu a že ji lze použít jako alternativní metodu, jejíž pozitivní ani negativní výsledky obvykle již nevyžadují žádné další potvrzování (10) (11). Zkušební laboratoř by měla před provedením studie zohlednit všechny dostupné informace o zkoušené látce. Mezi tyto informace patří totožnost a chemická struktura zkoušené látky, její fyzikálně-chemické vlastnosti, výsledky jakýchkoli jiných zkoušek toxicity in vitro a in vivo za použití zkoušené látky a toxikologické údaje o strukturně příbuzných látkách. Tyto informace je nutno posoudit, aby se zjistilo, zda je metoda LLNA: DA vhodná pro danou látku (s ohledem na neslučitelnost některých druhů chemických látek s metodou LLNA: DA (viz odstavec 5)), a také aby se usnadnila volba dávkování.
English: Despite the advantages of the LLNA: DA over B.6 and OECD Test Guideline 406 (14), there are certain limitations that may necessitate the use of B.6 or OECD Test Guideline 406 (e.g. the testing of certain metals, false positive findings with certain skin irritants (such as some surfactant-type substances) (6) (1 and Chapter B.42 in this Annex), solubility of the test substance). In addition, chemical classes or substances containing functional groups shown to act as potential confounders (16) may necessitate the use of guinea pig tests (i.e. B.6; OECD Test Guideline 406 (14)). Limitations that have been identified for the LLNA (1 and Chapter B.42 in this Annex) have been recommended to apply also to the LLNA: DA (10). Additionally, the use of the LLNA: DA might not be appropriate for testing substances that affect ATP levels (e.g. substances that function as ATP inhibitors) or those that affect the accurate measurement of intracellular ATP (e.g. presence of ATP degrading enzymes, presence of extracellular ATP in the lymph node). Other than such identified limitations, the LLNA: DA should be applicable for testing any substances unless there are properties associated with these substances that may interfere with the accuracy of the LLNA: DA. In addition, consideration should be given to the possibility of borderline positive results when Stimulation Index (SI) values between 1,8 and 2,5 are obtained (see paragraphs 31-32). This is based on the validation database of 44 substances using an SI ≥ 1,8 (see paragraph 6) for which the LLNA: DA correctly identified all 32 LLNA sensitisers, but incorrectly identified three of 12 LLNA non-sensitisers with SI values between 1,8 and 2,5 (i.e. borderline positive) (10). However, as the same dataset was used for setting the SI-values and calculating the predictive properties of the test, the stated results may be an over-estimation of the real predictive properties. PRINCIPLE OF THE TEST METHOD
Czech: PODSTATA ZKUŠEBNÍ METODY
English: Food Chem, Toxicol., 34, 999-1002.
Swedish: Food Chem, Toxicol., 34, 999–1002.
Finnish: 34, s. 999–1002.
Czech: Food Chem, Toxicol., 34, 999–1002.
Slovak: OECD (2010), Skin Sensitisation: Local Lymph Node Assay, Test Guideline No 429, Guidelines for the Testing of Chemicals, OECD, Paris. K dispozícii na stránke: [http://www.oecd.org/env/testguidelines].
Polish: Food Chem, Toxicol., 34, 999–1002.
Lithuanian: Food Chem, Toxicol., 34, 999–1002.
Maltese: Food Chem, Toxicol., 34, 999–1002.
English: Food Chem, Toxicol., 34, 985-997.
Portuguese: Toxicol., 34, 985-997.
Swedish: Food Chem, Toxicol., 34, 985–997.
Finnish: 34, s. 985–997.
Czech: Food Chem, Toxicol., 34, 985–997.
Slovak: Food Chem, Toxicol., 34, 985 – 997.
Polish: Food Chem, Toxicol., 34, 985–997.
Slovenian: Food Chem, Toxicol., 34, 985–997.
Estonian: Food Chem, Toxicol., 34, 985–997.
Lithuanian: Food Chem, Toxicol., 34, 985–997.
Maltese: Food Chem, Toxicol., 34, 985–997.
English: Toxicol., 36, 327-333.
Swedish: Toxicol., 36, 327–333.
Finnish: 36, s. 327–333.
Czech: Toxicol., 36, 327–333.
Slovak: Food Chem. Toxicol., 36, 327 – 333.
Polish: Toxicol., 36, 327–333.
Slovenian: Toxicol., 36, 327–333.
Estonian: Toxicol., 36, 327–333.
Lithuanian: Food Chem. Toxicol., 36, 327–333.
Maltese: Toxicol., 36, 327–333.
English: Toxicol., 146, 49-59.
Swedish: Toxicol., 146, 49–59.
Finnish: 146, s. 49–59.
Czech: Toxicol., 146, 49–59.
Slovak: Toxicol., 146, 49 – 59.
Polish: Toxicol., 146, 49–59.
Slovenian: Toxicol., 146, 49–59.
Estonian: Toxicol., 146, 49–59.
Lithuanian: Toxicol., 146, 49–59.
Maltese: Toxicol., 146, 49–59.
English: Meth., 58, 1-10.
Swedish: Meth., 58, 1–10.
Finnish: 58, s. 1–10.
Czech: Meth., 58, 1–10.
Slovak: Meth., 58, 1 – 10.
Polish: Meth., 58, 1–10.
Slovenian: Meth., 58, 1–10.
Estonian: Meth., 58, 1–10.
Lithuanian: Meth., 58, 1–10.
Maltese: Meth., 58, 1–10.
English: Meth., 58, 11-26.
Swedish: Meth., 58, 11–26.
Finnish: 58, s. 11–26.
Czech: Meth., 58, 11–26.
Slovak: Meth., 58, 11 – 26.
Polish: Meth., 58, 11–26.
Slovenian: Meth., 58, 11–26.
Estonian: Meth., 58, 11–26.
Lithuanian: Meth., 58, 11–26.
Maltese: Meth., 58, 11–26.
English: Meth., 160, 81-88.
Swedish: Meth., 160, 81–88.
Finnish: 160, s. 81–88.
Czech: Meth., 160, 81–88.
Slovak: Meth., 160, 81 – 88.
Polish: Meth., 160, 81–88.
Slovenian: Meth., 160, 81–88.
Estonian: Meth., 160, 81–88.
Lithuanian: Meth., 160, 81–88.
Maltese: Meth., 160, 81–88.
English: Meth., 72, 127-132.
Swedish: Meth., 72, 127–132.
Finnish: 72, s. 127–132.
Czech: Meth., 72, 127–132.
Slovak: Meth., 72, 127 – 132.
Polish: Meth., 72, 127–132.
Slovenian: Meth., 72, 127–132.
Estonian: Meth., 72, 127–132.
Lithuanian: Meth., 72, 127–132.
Maltese: Meth., 72, 127–132.
English: Biomat., 24, 27-34.
Swedish: Biomat., 24, 27–34.
Finnish: 24, s. 27–34.
Czech: Biomat., 24, 27–34.
Slovak: Biomat., 24, 27 – 34.
Polish: Biomat., 24, 27–34.
Slovenian: Biomat., 24, 27–34.
Estonian: Biomat., 24, 27–34.
Lithuanian: Biomat., 24, 27–34.
Maltese: Biomat., 24, 27–34.
English: Enzymol., 305, 346-370.
Swedish: Enzymol., 305, 346–370.
Finnish: 305, s. 346–370.
Czech: Enzymol., 305, 346–370.
Slovak: Enzymol., 305, 346 – 370.
Polish: Enzymol., 305, 346–370.
Slovenian: Enzymol., 305, 346–370.
Estonian: Enzymol., 305, 346–370.
Lithuanian: Enzymol., 305, 346–370.
Maltese: Enzymol., 305, 346–370.
English: Toxicol., 238, 71-89.
Swedish: Toxicol., 238, 71–89.
Finnish: 238, s. 71–89.
Czech: Toxicol., 238, 71–89.
Slovak: Toxicol., 238, 71 – 89.
Polish: Toxicol., 238, 71–89.
Slovenian: Toxicol., 238, 71–89.
Estonian: Toxicol., 238, 71–89.
Lithuanian: Toxicol., 238, 71–89.
Maltese: Toxicol., 238, 71–89.
English: Toxicol., 93, 13-31.
Swedish: Toxicol., 93, 13–31.
Finnish: 93, s. 13–31.
Czech: Toxicol., 93, 13–31.
Slovak: Toxicol., 93, 13 – 31.
Polish: Toxicol., 93, 13–31.
Slovenian: Toxicol., 93, 13–31.
Estonian: Toxicol., 93, 13–31.
Lithuanian: Toxicol., 93, 13–31.
Maltese: Toxicol., 93, 13–31.
English: Health, 53 563-79.
Portuguese: Health, 53, 563-79.
Swedish: Health, 53 563–79.
Finnish: Health 53, s. 563–79.
Czech: Health, 53 563–79.
Slovak: Healt., 53 563 – 579.
Polish: Health, 53, 563–79.
Slovenian: Health, 53563–79.
Estonian: Health, 53 563–79.
Lithuanian: Health, 53, 563–79.
Maltese: Health, 53 563–79.
English: Inter-laboratory reproducibility is determined during the pre-validation and validation processes, and indicates the extent to which a test can be successfully transferred between laboratories, also referred to as between-laboratory reproducibility (38). Intra-laboratory reproducibility A determination of the extent that qualified people within the same laboratory can successfully replicate results using a specific protocol at different times.
Finnish: Laboratorioidenvälinen uusittavuus määritetään esivalidointi- ja validointimenettelyissä, ja se osoittaa, missä määrin testi voidaan onnistuneesti toteuttaa eri laboratorioissa (38).
Czech: Mezilaboratorní reprodukovatelnost se určuje během předvalidačních a validačních postupů a ukazuje, do jaké míry lze zkoušku úspěšně přenášet mezi různými laboratořemi (38).
Estonian: Laboritevaheline reprodutseeritavus määratakse valideerimiseelsete ja valideerimisega seotud menetlustega ja see näitab, millisel määral võib uurimismeetodit edukalt üle viia ühest laborist teise (38).
English: Pharmacol., 34(3), 258-273.
French: Pharmacol., 34, 3-258.
Swedish: Pharmacol., 34(3), 258–273.
Finnish: Pharmacol 34(3), s. 258–273.
Czech: Pharmacol., 34(3), 258–273.
Slovak: Pharmacol., 34(3), 258 – 273.
Polish: Pharmacol., 34(3), 258–273.
Slovenian: Pharmacol., 34(3), 258–273.
Estonian: Pharmacol., 34(3), 258–273.
Lithuanian: Pharmacol., 34(3), 258–273.
Maltese: Pharmacol., 34(3), 258–273.
English: Pharmacol., 34(3), 274-286.
Swedish: Pharmacol., 34(3), 274–286.
Finnish: Pharmacol 34(3), s. 274–286.
Czech: Pharmacol., 34(3), 274–286.
Slovak: Pharmacol., 34(3), 274 – 286.
Polish: Pharmacol., 34(3), 274–286.
Slovenian: Pharmacol., 34(3), 274–286.
Estonian: Pharmacol., 34(3), 274–286.
Lithuanian: Pharmacol., 34(3), 274–286.
Maltese: Pharmacol., 34(3), 274–286.
English: Pharmacol., 34(3), 249-257.
French: Pharmacol., 34(3), 249- 257.
Swedish: Pharmacol., 34(3), 249–257.
Finnish: Pharmacol 34(3), s. 249–257.
Czech: Pharmacol., 34(3), 249–257.
Slovak: Pharmacol., 34(3), 249 – 257.
Polish: Pharmacol., 34(3), 249–257.
Slovenian: Pharmacol., 34(3), 249–257.
Estonian: Pharmacol., 34(3), 249–257.
Lithuanian: Pharmacol., 34(3), 249–257.
Maltese: Pharmacol., 34(3), 249–257.
English: Nonradioactive local lymph node assay: BrdU-ELISA Test Method Protocol (LLNA: BrdU-ELISA).
Italian: Nonradioactive local lymph node assay: BrdU-ELISA Test Method Protocol (LLNA: BrdU-ELISA). NIH Publication No.
Dutch: Nonradioactive local lymph node assay: BrdU-ELISA Test Method Protocol (LLNA: BrdU-ELISA). NIH Publication No.
Greek: BrdU-ELISA Test Method Protocol (LLNA: BrdU-ELISA). NIH Publication No.
Czech: Nonradioactive local lymph node assay: BrdU-ELISA Test Method Protocol (LLNA: BrdU-ELISA). NIH Publication No.
Polish: Nonradioactive local lymph node assay: BrdU-ELISA Test Method Protocol (LLNA: BrdU-ELISA). NIH Publication No.
Hungarian: Nonradioactive local lymph node assay: BrdU-ELISA Test Method Protocol (LLNA:BrdU-ELISA). NIH Publication No.
Slovenian: Nonradioactive local lymph node assay: BrdU-ELISA Test Method Protocol (LLNA: BrdU-ELISA). NIH Publication No.
Estonian: Nonradioactive local lymph node assay: BrdU-ELISA Test Method Protocol (LLNA: BrdU-ELISA). NIH Publication No.
Latvian: Nonradioactive local lymph node assay: BrdU-ELISA Test Method Protocol (LLNA: BrdU-ELISA). NIH Publication No.
English: Toxicol., 25, 129-134.
Swedish: Toxicol., 25, 129–134.
Finnish: 25, s. 129–134.
Czech: Toxicol., 25, 129–134.
Slovak: Toxicol., 25, 129 – 134.
Polish: Toxicol., 25, 129–134.
Slovenian: Toxicol., 25, 129–134.
Estonian: Toxicol., 25, 129–134.
Lithuanian: Toxicol., 25, 129–134.
Maltese: Toxicol., 25, 129–134.
English: Environ.l Health, 53, 563-79.
Portuguese: Health, 53, 563-79.
Swedish: Environ.l Health, 53, 563–79.
Finnish: Environ.l Health 53, s. 563–79.
Czech: Environ.l Health, 53, 563–79.
Slovak: Environ.l Health, 53, 563 – 579.
Polish: Environ.l Health, 53, 563–79.
Slovenian: Environ.l Health, 53, 563–79.
Estonian: Environ.l Health, 53, 563–79.
Lithuanian: Environ.l Health, 53, 563–79.
Maltese: Environ.l Health, 53, 563–79.
English: Inter-laboratory reproducibility is determined during the pre-validation and validation processes, and indicates the extent to which a test can be successfully transferred between laboratories, also referred to as between-laboratory reproducibility (33). Intra-laboratory reproducibility A determination of the extent that qualified people within the same laboratory can successfully replicate results using a specific protocol at different times.
Swedish: Reproducerbarheten mellan laboratorier fastställs under förvalideringen och valideringen och den indikerar i hur stor utsträckning ett test framgångsrikt kan överföras mellan laboratorier (33).
Finnish: Laboratorioidenvälinen uusittavuus määritetään esivalidointi- ja validointimenettelyissä, ja sillä osoitetaan, missä määrin testi voidaan onnistuneesti toteuttaa eri laboratorioissa (33).
Czech: Mezilaboratorní reprodukovatelnost se určuje během předvalidačních a validačních postupů a ukazuje, do jaké míry lze zkoušku úspěšně přenášet mezi různými laboratořemi (33).
Estonian: Laboritevaheline reprodutseeritavus määratakse valideerimiseelsete ja valideerimisega seotud menetlustega ja see näitab, millisel määral võib uurimismeetodit edukalt üle viia ühest laborist teise (33).